Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.
Lead Product(s): Sonelokimab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: MoonLake Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 05, 2022
Details:
Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by IL-17A and IL-17F.
Lead Product(s): Sonelokimab
Therapeutic Area: Dermatology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: MoonLake Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: $230.0 million
Deal Type: Agreement October 04, 2021
Details:
In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.
Lead Product(s): L-DOS47
Therapeutic Area: Oncology Product Name: L-DOS47
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Moffitt Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 12, 2020
Details:
Topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer will be published at the ASCO 2020 Annual Conference.
Lead Product(s): L-DOS47,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020